Strides Pharma Science (NSE:STAR) Total Debt per Share: ₹190.73 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:STAR Strides Pharma Science Ltd NSE:STAR
65 GF Score
Price ₹1,025.00
GF Value ₹764.20
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Strides Pharma Science Total Debt per Share?

Strides Pharma Science NSE:STAR -4.46% 65 Total Debt per Share is ₹190.73 as of Mar. 2026. GuruFocus rates NSE:STAR with a GF Score™ of 65/100 and a GF Value™ of ₹764.20 (Significantly Overvalued). The stock has 2 warning signs investors should review.

₹190.73 (As of Mar. 2026)

Total Debt per Share is calculated as total debt divided by Shares Outstanding (EOP). Total debt is calculated as Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Strides Pharma Science's Total Debt Per Share for the quarter that ended in Mar. 2026 was ₹190.73.

Strides Pharma Science Total Debt per Share Historical Data

* Premium members only.

The historical data trend for Strides Pharma Science's Total Debt per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Strides Pharma Science Total Debt per Share Chart

Strides Pharma Science Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Debt per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 336.90 335.49 273.87 203.95 190.73

Strides Pharma Science Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Debt per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 203.95 0.00 200.04 0.00 190.73
NSE:STAR
65GF Score
Strides Pharma Science Ltd NSE:STAR
Total Debt per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Strides Pharma Science Total Debt per Share Calculation

Strides Pharma Science's Total Debt Per Share for the fiscal year that ended in Mar. 2026 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(6,042+11,538)/92
=190.73

Strides Pharma Science's Total Debt Per Share for the quarter that ended in Mar. 2026 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(6,042+11,538)/92
=190.73

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Debt per Share →
What does a Total Debt per Share of ₹190.73 mean?
Strides Pharma Science (NSE:STAR) has a Total Debt per Share of ₹190.73 as of Mar. 2026. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on Strides Pharma Science and its competitors.
Is Strides Pharma Science's Total Debt per Share too high?
Strides Pharma Science's current Total Debt per Share is ₹190.73. Overall, Strides Pharma Science has a GF Score™ of 65/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Strides Pharma Science's Total Debt per Share compare to ZTS?
Strides Pharma Science's Total Debt per Share of ₹190.73 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Debt per Share for a Drug Manufacturers company?
A good Total Debt per Share depends on the Drug Manufacturers industry context. However, Total Debt per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Debt per Share mean?
A high Total Debt per Share can signal that a stock is expensive relative to its fundamentals. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on Strides Pharma Science and its competitors. Strides Pharma Science's current Total Debt per Share is ₹190.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Strides Pharma Science stock overvalued right now?
Based on GuruFocus' analysis, Strides Pharma Science (NSE:STAR) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹764.20, compared to a current price of ₹1,025.00 — trading 34.1% above its estimated fair value. The current Total Debt per Share is ₹190.73. Strides Pharma Science's overall GF Score™ is 65/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Debt per Share calculated?
Total Debt per Share is calculated from a company's financial statements. For Strides Pharma Science (NSE:STAR), the current Total Debt per Share is ₹190.73 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Strides Pharma Science (NSE:STAR) Overvalued in 2026?

Based on GuruFocus' analysis, Strides Pharma Science stock appears to be overvalued. The current stock price of ₹1,025.00 is trading 34.1% above its estimated GF Value™ of ₹764.20. GuruFocus considers Strides Pharma Science to be Significantly Overvalued.

Key valuation signals for NSE:STAR:

  • Total Debt per Share: ₹190.73
  • GF Value™: ₹764.20 vs. price of ₹1,025.00 (34.1% above fair value)
  • GF Score™: 65/100 with 2 warning signs

No single metric tells the full story. See the NSE:STAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Strides Pharma Science Business Description

Other Exchanges 532531:India
Address Bannerghatta Road, Strides House, Bilekahalli, Bengaluru, KA, IND, 560076
Strides Pharma Science Ltd develops and manufactures a wide range of IP-led niche pharmaceutical products. Its diverse portfolio spans complex generics across multiple dosage forms, including tablets, hard capsules, sachets, liquids, nasal sprays, topicals, and controlled substances. It also manufactures drugs in the anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for its institutional business. The customers for this business include institutionally funded aid projects and procurement agencies. With its R&D, integration, and distribution network, the company brings differentiated products to market across the U.S., Australia, Europe, Africa, and Emerging Markets. Geographically, it generates maximum revenue from North America.
65GF Score

Get the complete analysis for NSE:STAR

Total Debt per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,025.00
Price
₹764.20
GF Value